Ligand pays $30M upfront in royalty deal; Actym extends its Series A; Gero raises $6M

Ligand acquires partial royalty rights to epilepsy candidate: Ligand said Wednesday that it’s paying $30 million upfront to Ovid Therapeutics as part of a deal to acquire 13% of royalties and milestones for soticlestat, which is currently in Phase III trials for two types of epilepsy: Lennox-Gastaut syndrome and Dravet syndrome. Back in 2021, Ovid sold the soticlestat rights to Takeda for $196 million upfront, $660 million in milestones, and tiered royalties. Ovid now expects its cash to last into 2026.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

Study offers insight into early developmental risk factors for ADHD

Several early developmental factors are associated with an increased risk of ADHD during childhood and adolescence.

May 29, 2024

COVID Infection May Impair Semen Quality, Even After Mild Cases

Semen quality remained impaired more than 3 months after a mild COVID-19 infection, according to a small study from Spain involving unvaccinated men. Testing performed

July 1, 2023

Housing instability heightens Alzheimer’s risk in veterans

In a recent study published in Journal of the American Geriatrics Society, Veterans with housing instability were 53% more likely to receive a diagnosis of

December 6, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.